IPO Boutique

Apellis Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Apellis Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Apellis PharmaceuticalsAPLS -
NASDAQ
$13.00-$15.00 $14.00 $14.5010.7 million11/9/2017
Citigroup, J.P. Morgan, Evercore ISI
Co-Manager(s):
Health Care
Filing(s):

1st Filed 2015-10-14
Filed 2017-10-13
Terms added 2017-10-30
Final Prospectus 2017-11-09



Apellis Pharmaceuticals Quote & Chart - Click for current quote - APLS

About Apellis Pharmaceuticals (adapted from Apellis Pharmaceuticals prospectus):
They are a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "APLS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved